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ABSTRACT
Background
Several studies have demonstrated that patients with childhood acute lymphoblastic leukemia
presenting with mild anemia at diagnosis have an increased risk of poor outcome compared to
patients with more severe anemia. However, it has not been reported whether there is any cor-
relation between degree of anemia and leukemia subtype.
Design and Methods
In a cohort of 1162 patients with childhood acute lymphoblastic leukemia we analyzed whether
there was a correlation between degree of anemia and leukemia subtype. We also studied the
association between degree of anemia and event-free survival within the subtypes.
Results
Hemoglobin levels at diagnosis were distributed in a non-random pattern. The degree of ane-
mia was significantly different for three distinct groups of patients compared to the remaining
patients (mean hemoglobin; T-cell leukemia: 106 g/L versus 76 g/L (precursor B-cell acute
lymphoblastic leukemia); within precursor B-cell ALL: TEL-AML1 positive: 68 g/L versus 79 g/L;
BCR-ABL positive: 93 g/L versus 76 g/L; each p<0.05). Furthermore, in contrast to the entire
study group, patients with T-cell leukemia, TEL-AML1+, and BCR-ABL+ precursor B-cell leukemia
had a more favorable prognosis if presenting with a higher hemoglobin level (≥80 g/L).
Conclusions
These observations indicate that the formerly reported direct correlation between severity of
anemia and survival in childhood acute lymphoblastic leukemia mainly reflects differences in
the degree of anemia between distinct biological subgroups with different treatment outcomes.
On the other hand, the inverse relationship between severity of anemia and survival found with-
in specific subgroups suggests that very low hemoglobin levels at diagnosis are associated with
more advanced disease in these subgroups.
Key words: childhood acute lymphoblastic leukemia, anemia, myeloid suppression, TEL-AML1.
Citation: Teuffel O, Stanulla M, Cario G, Ludwig WD, Rottgers S, Schafer BW, Zimmermann M,
Schrappe M, and Niggli FK. Anemia and survival in childhood acute lymphoblastic leukemia.
Haematologica 2008; 93:1652-1657. doi: 10.3324/haematol.13156  
©2008 Ferrata Storti Foundation. This is an open-access paper.
Introduction
Anemia is common in patients with newly diag-
nosed childhood acute lymphoblastic leukemia (ALL).
Several studies have demonstrated a correlation
between degree of anemia and survival.1-4 Evidence
suggests that patients presenting with higher hemoglo-
bin (Hb) levels at diagnosis have an increased risk of
poor outcome compared to patients with lower Hb
levels. However, in multivariate models, Hb was not
identified as an independent risk factor.3,4 Despite the
fact that Hb is not applicable for risk stratification in
clinical trials, the relationship between anemia and
prognosis might hold some important biological infor-
mation that warrants further investigation.  
The pathomechanism of anemia in childhood ALL is
not completely understood. Anemia in children with
cancer is associated with decreased erythropoietic
activity but not with inadequate erythropoietin pro-
duction, leading to the assumption that anemia in
patients with leukemia mainly results from suppres-
sion of normal hematopoiesis in the bone marrow by
infiltrating blasts.5,6
To further understand the pathophysiology of ane-
mia in childhood ALL, it is important to consider the
heterogeneity of diseases in these patients, including
immunological subgroups (precursor B-cell ALL versus
T-cell leukemia) and cytogenetic subgroups (e.g. TEL-
AML1, E2A-PBX1, BCR-ABL, hyperdiploid karyotype
with >50 chromosomes, and MLL gene rearrange-
ments). 
The differences in clinical features at presentation
between patients with T-cell leukemia and precursor
B-cell ALL are well recognized and include higher Hb
levels in patients with T-cell leukemia.7-9 However, the
prognostic influence of the initial Hb level in T-cell
leukemia is controversial. In some studies, a higher Hb
level was associated with a worse prognosis.10,11 In
other series, there was no association, or even an
opposite association.12,13 The Hb level at diagnosis is
apparently not suitable for application in risk stratifica-
tion strategies in current clinical trials.14
Precursor B-cell ALL is a heterogeneous disease com-
prising several distinct biological subtypes that are
associated with different outcomes. Patients with
t(1;19) leading to a E2A-PBX1 gene fusion, hyper-
diploidy involving more than 50 chromosomes, or
TEL-AML1 gene fusion have a favorable outcome,
whereas those with t(4;11) leading to a MLL-AF4 gene
fusion and a t(9;22) leading to a BCR-ABL gene fusion
have a dismal prognosis.15 Despite the accurate analy-
sis of the incidence and clinical relevance of these sub-
types, it has not been reported whether there is any
relationship between cytogenetic subtypes and degree
of anemia.16-21
In the present study, we evaluated whether there is
a correlation between degree of anemia and leukemia
subtype. Furthermore, we studied the association
between degree of anemia and event-free survival
(EFS) within these subtypes of leukemia. 
Design and Methods
The present study utilized initial diagnostic character-
istics of patients with ALL enrolled in the multicenter
ALL-BFM 95 trial of the Berlin-Frankfurt-Munster (BFM)
study group between April 1995 and June 2000 who
underwent screening for fusion genes (TEL-AML1, BCR-
ABL, MLL-AF4).22 Differences in the distribution of
parameters between subgroups of patients were exam-
ined using the χ2 or Fisher´s exact test. Survival probabil-
ities were calculated using the Kaplan and Meier
method with differences compared by the log-rank test;
standard error were calculated according to
Greenwood.23-25 The probability of EFS (pEFS) was cal-
culated from the date of diagnosis to the first event
(death from any cause, tumor progression/relapse or
non-response, or second malignancy) or to the date of
last follow-up. The prognostic impact of anemia on
treatment outcome was analyzed together with other
known prognostic factors using Cox regression analy-
sis.26 Statistical analyses were performed using the SAS
program (SAS-PC, version 9.1, Cary, NC: SAS Institute
Inc.). The patients’ follow-up data were updated as of
October 2005.
Results 
Initially, we analyzed the Hb levels and the relation
between anemia and survival in the entire group of
patients. Based on 1162 peripheral blood samples, the
mean Hb level at diagnosis was 80 g/L (standard devia-
tion 27 g/L) (Table 1). Patients who presented with high-
er Hb levels at diagnosis (Hb ≥80 g/L) had an increased
risk of poor outcome compared to patients with lower
Hb levels (Hb <80 g/L) (pEFS: 0.76 versus 0.8, log-rank
p=0.05).
To characterize the distribution of anemia in the het-
erogeneous group of patients with childhood ALL, the
Hb levels were analyzed according to immunopheno-
typic and cytogenetic subtypes of ALL (Table 1).
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Table 1. Hemoglobin levels (in g/L) according to the immunologi-
cal and cytogenetic subtypes of childhood acute lymphoblastic
leukemia.
n Hb, Hb, Hb, Hb, p-value
mean s.d. median range
All types of ALL 1162 80 27 77 19-167
T-cell leukemia 138 106 28 108 30-167 <0.001
Precursor B ALL* 981 76 25 74 19-163
TEL-AML1 positive 241 68 20 66 19-163 <0.001
TEL-AML1 negative 740 79 26 78 25-156
DNA index ≥1.16 157 76 22 77 31-138 0.91
DNA index <1.16 612 77 26 74 25-163
BCR-ABL positive 23 93 31 86 34-156 0.01
BCR-ABL negative 946 76 25 74 19-163
MLL-AF4 positive 11 75 33 72 30-129 0.52
MLL-AF4 negative 633 81 28 80 19-167
*E2A-PBX1 positive precursor B-ALL were not analyzed separately. 
Patients with T-cell leukemia (n=138) presented with
significantly higher Hb levels at diagnosis than patients
with precursor B-cell ALL (n=981) (mean Hb level, 106
g/L versus 76 g/L; p<0.001). Within the group of patients
with T-cell leukemia, an inverse relation between Hb
level and hyperleukocytosis (leukocytes ≥100×109/L)
was found (Table 2A). There was no association
between degree of anemia and age among patients with
T-cell leukemia (Table 2B).
Within the heterogeneous group of precursor B-cell
ALL, the lowest mean Hb level was associated with
TEL-AML1+ leukemia (n=241) (mean Hb level 68 g/L).
The mean Hb level was 75 g/L in MLL-AF4+ leukemia
(n=11), 76 g/L in hyperdiploid karyotype leukemia
(n=157), and 93 g/L in BCR-ABL+ leukemia (n=23).
Considering only precursor B-cell ALL, the observed Hb
levels were significantly different (p<0.05) for both the
TEL-AML1+ and BCR-ABL+ subgroups compared to the
remaining precursor B-cell ALL group (Table 1). Again,
the association between anemia and hyperleukocytosis,
and the influence of age, was evaluated for these two
subgroups. As for T-cell leukemia, an inverse relation
was found between Hb level and hyperleukocytosis
(leukocytes ≥100×109/L) which was, however, only sta-
tistically significant in the TEL-AML1+ subgroup (Table
2A). Furthermore, younger age (<10 years) was associat-
ed with lower Hb levels at diagnosis in both groups
(Table 2B). 
Patients enrolled in the ALL-BFM 95 trial did not
undergo screening for the E2A-PBX1 gene fusion.
Therefore, anemia could not be analyzed separately in
this subgroup of patients. 
The second aim of this retrospective study was to
evaluate whether there is an association between Hb
level and prognosis within the subgroups. Due to a lim-
ited number of patients in the MLL-AF4 group, this
evaluation could only be performed for T-cell leukemia,
TEL-AML1+, BCR-ABL+, and hyperdiploid karyotype
precursor B-cell ALL. 
Among children with T-cell leukemia, the Hb level at
diagnosis was significantly associated with EFS. Patients
presenting with lower Hb levels at diagnosis had an
increased risk of poor outcome compared to patients
with higher Hb level [(pEFS: 0.77 (Hb ≥80 g/L, n=114)
versus 0.54 (Hb <80 g/L, n=24), p=0.03, and 0.82 (Hb
≥110 g/L, n=67) versus 0.65 (Hb <110 g/L, n=71),
p=0.03)] (Figures 1 and 2). There was a trend for a simi-
lar difference in the TEL-AML1+ subgroup. Again, an
advantage was observed for patients with higher Hb
level as compared to those with lower Hb levels [(pEFS:
0.97 (Hb ≥80 g/L, n=66) versus 0.89 (Hb <80 g/L,
n=175), log-rank p=0.12, 6-year pEFS p=0.01)]. In addi-
tion, there was a significant association between ane-
mia and EFS within the BCR-ABL+ subgroup. Treatment
failed in all patients who were diagnosed with BCR-ABL
rearrangement in combination with lower Hb level at
diagnosis [(pEFS: 0.35 (Hb ≥80 g/L, n=17) versus 0 (Hb
<80 g/L, n=8), p=0.02)]. No substantial association was
found between Hb level and prognosis for hyperdiploid
karyotype leukemias [(pEFS: 0.85 (Hb ≥80 g/L, n=74)
versus 0.88 (Hb <80 g/L, n=86), log-rankp=0.52, 6-year
pEFS p=0.51)]. 
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Table 2. Hemoglobin levels (in g/L) according to initial leukocyte
count (A) and age (B).
Leukocytes [×109/L] <100 ≥100 p-value
n Hb, mean n Hb, mean
A
T-cell leukemia 75 112 63 99 0.004
TEL-AML1 positive* 231 68 10 50 0.002
BCR-ABL positive* 18 96 7 86 0.54
Age [years] <10 ≥10 p-value
n Hb, mean n Hb, mean
B
T-cell leukemia 81 103 57 110 0.14
TEL-AML1 positive* 220 66 21 79 0.02
BCR-ABL positive* 17 83 8 114 0.05
*Precursor B acute lymphoblastic leukemia.  
Figure 1. Kaplan-Meier estimate of event-free survival of 138 chil-
dren with T-cell leukemia according to the hemoglobin level at
diagnosis. The cut-off hemoglobin level of 80 g/L is the mean
value of the entire study group.  
Figure 2. Kaplan-Meier estimate of event-free survival of 138 chil-
dren with T-cell leukemia according to hemoglobin level at diagno-
sis. The cut-off hemoglobin level of 110 g/L is the mean value
within the group of patients with T-cell leukemias. 
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To further evaluate the prognostic impact of Hb in T-
lineage and TEL-AML1+ ALL, Cox models were applied
including factors such as Hb level (≥80 g/L) and leuko-
cyte count (≥100×109/L) at diagnosis, age (≥10 years),
and prednisone response (the presence of ≥1,000 blasts
per microliter of peripheral blood at day 8 was defined
as a prednisone poor response). Due to the limited num-
ber of patients, no Cox model was constructed for the
BCR-ABL group. In T-cell leukemia, only a prednisone
poor response was an independent prognostic factor
(RR=5.74, 95%CI 2.62–11.44, p<0.001). All data includ-
ing those for Hb, leukocytes, and age are presented in
Table 3A. Applying the Cox model to the TEL-AML1
subgroup, no independent risk factor could be identified
(Table 3B). Thus, when adjusted for other risk factors,
Hb is not an independent risk factor. 
Discussion
Anemia is a consistent hematologic finding at the
diagnosis of childhood ALL. Here, we confirm the
results of former studies in which a relationship
between degree of anemia and outcome was observed.
Severe anemia at diagnosis (Hb <80 g/L) was again asso-
ciated with a better EFS than that in patients with only
mild anemia (Hb ≥80g/L). However, the observed differ-
ence was only moderate and did not take into consider-
ation the heterogeneity of childhood ALL.  
Until now, no studies evaluated a possible correlation
between degree of anemia and leukemia subtype. Our
study demonstrates that Hb levels at diagnosis are dis-
tributed in a non-random pattern in childhood ALL. As
expected, patients with T-cell leukemia presented with
significanty higher Hb levels at diagnosis than did
patients with precursor B-cell ALL. Although the basis
for this difference is not well understood, it is likely that
biological regulation of bone marrow infiltration, cell
clone proliferation, and circulating peripheral blasts sub-
stantially differentiate T-cell leukemia from precursor B-
cell ALL. In addition to the difference in the Hb level
between T-lineage ALL and precursor B-cell leukemias,
we also found a statistically significant difference in Hb
level between both BCR-ABL+ and TEL-AML1+ ALL and
precursor B-cell ALL without these fusions. Several
studies have analyzed the clinical and biological fea-
tures in ALL patients carrying the translocation t(12;21)
leading to the TEL-AML1 gene fusion.27-38 None of those
studies reported a low Hb level to be associated with
TEL-AML1. One study addressed this issue, but failed to
demonstrate a correlation between Hb and TEL-AML1,
probably due to the limited number of patients ana-
lyzed (11/51 patients TEL-AML1+).39 However, a possi-
ble association between lower Hb levels at diagnosis
and the TEL-AML1 subtype were observed for the first
time recently by a group from China.40 The analysis of
95 pediatric ALL patients including 20 TEL-AML1+ cases
revealed a significantly lower Hb level in the TEL-
AML1+ patients than in the other patients (61 g/L versus
76 g/L; p=0.003). Their findings have now been con-
firmed by our data. We add significant information hav-
ing evaluated a much larger group of patients and hav-
ing conducted a comprehensive subgroup analysis.   
Our data strongly suggest that there is a correlation
between leukemia subtype and the degree of anemia
indicating distinct mechanisms in the formation of ery-
thropoietic insufficiency. Lower Hb levels (Hb <80 g/L)
were more often diagnosed in leukemia subtypes asso-
ciated with a favorable outcome (TEL-AML1+, hyper-
diploid karyotype). In contrast, more aggressive
leukemia subtypes (T-cell leukemia and BCR-ABL+ pre-
cursor B-cell leukemia) were associated with higher Hb
levels (Hb ≥80 g/L).22 We suppose that the correlation
between degree of anemia and survival is due to the cor-
relation between degree of anemia and the distinct bio-
logical subgroups that are associated with different out-
comes. 
Evaluating the TEL-AML1+ subgroup, anemia was
more pronounced among younger patients (<10 years).
There was a trend for a similar difference in the BCR-
ABL+ subgroup. It is possible that lower baseline Hb lev-
els in the younger population before developing
leukemia might contribute to this finding; however, an
additional impact of other biological factors cannot be
excluded. Patients carrying the TEL-AML1 translocation
are overrepresented in the younger age group (<10
years). We think it is rather unlikely that lower baseline
Hb levels before developing leukemia exclusively con-
tributes to the strong association of TEL-AML1 and
severe anemia (Hb <80 g/L). This assumption is based
upon the observation that the mean Hb level was lower
in the TEL-AML1 subgroup than in the other subgroups
in older patients (>10 years).  
As regards the predictive power of Hb level in sub-
groups, the literature data on the prognostic influence of
Hb in T-cell leukemia are controversial.10-13 Based on our
data, higher Hb levels in this group of patients were
clearly associated with better outcome compared to
lower Hb levels. We observed a similar trend in the TEL-
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Table 3. Cox regression analysis in T-cell leukemia (A) and TEL-
AML1 positive precursor B acute lymphoblastic leukemia (B): Risk
ratios and 95% confidence interval.
Risk factorsa RRb LL UL p
A
Moderate/mild anemia 0.71 0.34 1.48 0.36
Hyperleukocytosis 1.36 0.67 2.75 0.40
Older age 1.96 0.98 3.93 0.06
Prednisone poor response 5.47 2.62 11.44 <0.001
Risk factorsa RRb LL UL p
B
Moderate/mild anemia 0.45 0.13 1.57 0.21
Hyperleukocytosis 0.36 0.03 3.99 0.40
Older age 0.76 0.10 5.85 0.79
Prednisone poor response 4.88 0.88 27.17 0.07
RR: risk ratios; LL: lower limit; UL: upper limit. adefinition of risk factors: moder-
ate/mild anemia (Hb ≥80 g/L), hyperleukocytosis (leukocyte count
≥100×109/L), older age (≥10 years), prednisone poor response (the presence of
≥1,000 blasts/µL peripheral blood at day 8 of treatment). bRR related to the first
event after diagnosis (death from any cause, tumor progression/relapse or non-
response, or second malignancy) 
AML1+ subgroup. Due to an unusual late relapse, there
was no overall significance in this group using the log-
rank test, however, EFS at 6 years was significantly dif-
ferent between the two groups. Despite a limited num-
ber of patients (n=25), estimation of EFS revealed strik-
ing differences within the subgroup of BCR-ABL+ pre-
cursor B-cell leukemia. Again, a low Hb level at diagno-
sis was an adverse prognostic marker. Despite the
reported (univariate) association between anemia and
EFS within the mentioned subgroups, the Hb level at
diagnosis was not an independent risk factor and, there-
fore, of negligible value for risk assignment. The predic-
tive power of treatment response was much stronger
than that of the initial Hb level.  
To summarize, initial degree of anemia in childhood
ALL is non-randomly distributed. Moreover, in contrast
to the group of patients considered as a whole, patients
with T-cell leukemia, TEL-AML1+, and BCR-ABL+ pre-
cursor B-cell leukemia have a more favorable prognosis
if presenting with higher Hb levels. Given that it was
observed in several series that a higher Hb level is asso-
ciated with poorer outcome, it was assumed that this
reflects conditions with a high proliferation rate of an
aggressive leukemic cell clone (shorter history in fast dis-
ease).41,42 Based on our data, this hypothesis is not sus-
tainable for (at least) the three ALL subtypes mentioned
above. This is further supported by the observation that
hyperleukocytosis was associated with lower Hb levels.
We suggest that lower Hb levels or severe anemia at
diagnosis might correspond to conditions of advanced
disease. It is possible that patients presenting with high-
er Hb levels or mild anemia are detected at an early
stage of disease, and are, therefore, more susceptible to
chemotherapeutic interventions.  
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